Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Current Deferred Revenue (2024 - 2025)

Gossamer Bio's Current Deferred Revenue history spans 2 years, with the latest figure at $20.0 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 17.3% year-over-year to $20.0 million; the TTM value through Dec 2025 reached $20.0 million, up 17.3%, while the annual FY2025 figure was $20.0 million, 17.3% up from the prior year.
  • Current Deferred Revenue reached $20.0 million in Q4 2025 per GOSS's latest filing, down from $24.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $66.7 million in Q2 2024 to a low of $17.0 million in Q4 2024.